A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
This randomized phase III trial studies how well methotrexate works compared to dactinomycin
in treating patients with low-risk gestational trophoblastic neoplasia. Drugs used in
chemotherapy, such as methotrexate and dactinomycin, work in different ways to stop the
growth of tumour cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. It is not yet known whether methotrexate is more effective
than dactinomycin in treating gestational trophoblastic disease.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society